INTRODUCTION
============

Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a highly debilitating and irreversible neurological disorder presenting symptoms of progressive sensorimotor and autonomic neuropathy \[[@R1],[@R2],[@R3]\]. TTR-FAP is caused by misfolding of the transthyretin (TTR) protein leading to protein aggregation and the formation of amyloid fibrils and, ultimately, to amyloidosis (commonly in the peripheral and autonomic nervous system and the heart) \[[@R4],[@R5]\]. TTR-FAP usually proves fatal within 7--12 years from the onset of symptoms, most often due to cardiac dysfunction, infection, or cachexia \[[@R6],[@R7]^▪▪^\].

The prevalence and disease presentation of TTR-FAP vary widely within Europe. In endemic regions (northern Portugal, Sweden, Cyprus, and Majorca), patients tend to present with a distinct genotype in large concentrations, predominantly a Val30Met substitution in the *TTR* gene \[[@R8]--[@R10]\]. In other areas of Europe, the genetic footprint of TTR-FAP is more varied, with less typical phenotypic expression \[[@R6],[@R11]\]. For these sporadic or scattered cases, a lack of awareness among physicians of variable clinical features and limited access to diagnostic tools (i.e., pathological studies and genetic screening) can contribute to high rates of misdiagnosis and poorer patient outcomes \[[@R1],[@R11]\]. In general, early and late-onset variants of TTR-FAP, found within endemic and nonendemic regions, present several additional diagnostic challenges \[[@R11],[@R12],[@R13],[@R14]\].

Delay in the time to diagnosis is a major obstacle to the optimal management of TTR-FAP. With the exception of those with a clearly diagnosed familial history of FAP, patients still invariably wait several years between the emergence of first clinical signs and accurate diagnosis \[[@R6],[@R11],[@R14]\]. The timely initiation of appropriate treatment is particularly pertinent, given the rapidity and irreversibility with which TTR-FAP can progress if left unchecked, as well as the limited effectiveness of available treatments during the later stages of the disease \[[@R14]\]. This review aims to consolidate the existing literature and present an update of the best practices in the management of TTR-FAP in Europe. A summary of the methods used to achieve a TTR-FAP diagnosis is presented, as well as a review of available treatments and recommendations for treatment according to disease status. 

![no caption available](coneu-29-s14-g001){#FB1}

METHODOLOGY
===========

This article is based on outcomes from two roundtable meetings of the European Network for TTR-FAP (ATTReuNET) (November 2012 and March 2014) and a comprehensive review of the published literature. The group comprised 14 TTR-FAP experts from 10 European countries (Bulgaria, Cyprus, France, Germany, Italy, the Netherlands, Portugal, Spain, Sweden, and Turkey; Tables S1 and S2), and includes nine National Reference Centres (NRCs). The experts completed a semistructured questionnaire on the local practice of TTR-FAP disease management in preparation for both meetings (Table S3). Group members are clinicians from a variety of specialties, including neurology, internal medicine, cardiology, and nephrology.

Electronic database searches (NCBI PubMed) formed the basis of the literature search within the time frame (1952 to December 2014). Key search terms included 'transthyretin familial amyloid polyneuropathy', 'familial amyloid polyneuropathy', 'transthyretin amyloidosis', 'TTR-FAP', 'TTR-FAP and Europe', and 'TTR-FAP and Bulgaria/Cyprus/France/Germany/Italy/the Netherlands/Portugal/Spain/Sweden/Turkey'.

Misdiagnosis of transthyretin familial amyloid polyneuropathy
-------------------------------------------------------------

The diagnosis of TTR-FAP presents a significant challenge to the physician. Given its rarity within the general population, there is a reduced likelihood of the evaluating physician immediately recognizing the symptoms of TTR-FAP without first mistaking them for a more widely seen disorder. Common misdiagnoses made prior to correctly diagnosing TTR-FAP include idiopathic axonal polyneuropathy, chronic inflammatory demyelinating polyneuropathy, and lumbar spinal stenosis \[[@R1],[@R15]\]. Diabetes or chronic alcoholism may induce polyneuropathies similar to TTR-FAP \[[@R10]\]. Further potential misdiagnoses include Charcot--Marie--Tooth neuropathy or motor neuron disease \[[@R1]\].

The commonly held misconception that TTR-FAP is a disease of young people with an established family history and a classic presentation means that patients exhibiting classic neurological symptoms without, or with an unknown, familial history may be overlooked or misdiagnosed \[[@R1]\]. It is often the case that patients presenting with inconsistent autonomic symptoms are later identified as new clinical phenotypes \[[@R11],[@R12],[@R13],[@R14]\].

Diagnostic drivers
------------------

The diagnostic process is driven by two components. The first is clinical suspicion, which permits a tentative diagnosis of TTR-FAP through patient history and physical examination (symptoms and signs); the second is diagnostic confirmation using accurate diagnostic tools, including histopathology and genetic analysis (Table [1](#T1){ref-type="table"}) \[[@R8],[@R10],[@R12],[@R13],[@R15]--[@R17]\]. Following a clinical suspicion, positive results from both biopsy and genetic analysis are essential to distinguish TTR-FAP from the large number of peripheral neuropathies \[[@R1],[@R13],[@R18]\], formally diagnose TTR-FAP, and specify the genetic variant \[[@R19]\].

### Clinical diagnosis

Patients with TTR-FAP can present with a range of symptoms \[[@R11]\], and care should be taken to acquire a thorough clinical history of the patient as well as a family history of genetic disease. Delay in diagnosis is most pronounced in areas where TTR-FAP is not endemic or when there is no positive family history \[[@R1]\]. TTR-FAP and TTR-familial amyloid cardiomyopathy (TTR-FAC) are the two prototypic clinical disease manifestations of a broader disease spectrum caused by an underlying hereditary ATTR amyloidosis \[[@R19]\]. In TTR-FAP, the disease manifestation of neuropathy is most prominent and definitive for diagnosis, whereas cardiomyopathy often suggests TTR-FAC. However, this distinction is often superficial because cardiomyopathy, autonomic neuropathy, vitreous opacities, kidney disease, and meningeal involvement all may be present with varying severity for each patient with TTR-FAP.

Among early onset TTR-FAP with usually positive family history, symptoms of polyneuropathy present early in the disease process and usually predominate throughout the progression of the disease, making neurological testing an important diagnostic aid \[[@R14]\]. Careful clinical examination (e.g., electromyography with nerve conduction studies and sympathetic skin response, quantitative sensation test, quantitative autonomic test) can be used to detect, characterize, and scale the severity of neuropathic abnormalities involving small and large nerve fibres \[[@R10]\]. Although a patient cannot be diagnosed definitively with TTR-FAP on the basis of clinical presentation alone, symptoms suggesting the early signs of peripheral neuropathy, autonomic dysfunction, and cardiac conduction disorders or infiltrative cardiomyopathy are all indicators that further TTR-FAP diagnostic investigation is warranted. Late-onset TTR-FAP often presents as sporadic cases with distinct clinical features (e.g., milder autonomic dysfunction) and can be more difficult to diagnose than early-onset TTR-FAP (Table [2](#T2){ref-type="table"}) \[[@R1],[@R11],[@R12],[@R13],[@R14],[@R20]\].

### Histopathology

The aim of histopathological analysis is to obtain direct evidence for amyloid deposits through biopsy on several possible tissue sites, including the labial salivary gland, abdominal subcutaneous adipose tissue, gastrointestinal tract, nerve tissue, and other organs with evidence of involvement (e.g., heart, kidney) (Table [1](#T1){ref-type="table"}) \[[@R1],[@R13],[@R21]^▪▪^,[@R22]--[@R25]\]. Biopsy tissue is Congo red-stained in order to visualize the extracellular amyloid deposits by their characteristic apple-green birefringence after crosspolarized light examination \[[@R26],[@R27]\]. Following biopsy, immunohistochemistry can be used to confirm that amyloid is formed by TTR.

Abdominal fat tissue biopsy and rectal biopsy are the most frequently performed according to the members of ATTReuNET, followed by sural nerve and labial salivary gland biopsy (Table [3](#T3){ref-type="table"}). The selection of biopsy site varies widely between treatment centres and is largely dependent on the expertise of a particular team, whereas access to these facilities depends on the geographical area in which the patient resides. For example, biopsy sensitivity depends on the protocol for Congo red staining, the experience of the pathologist in reading the slides, and the variable sensitivity, as well as the specificity of the antibodies used for standard immunohistochemistry (Table [1](#T1){ref-type="table"}) \[[@R1],[@R10]\]. Therefore, the characterization of amyloid deposits should preferably be performed by experienced pathologists in order to minimize the risk of misdiagnosis \[[@R16],[@R25],[@R28],[@R29]\]. Conducting repeat biopsy at different sites to confirm diagnosis is not uncommon (Table [3](#T3){ref-type="table"}) (Adams, personal communication, 2014).

### Genetic analysis

Genetic testing is carried out to allow detection of specific amyloidogenic *TTR* mutations (Table [1](#T1){ref-type="table"}), using varied techniques depending on the expertise and facilities available in each country (Table S2). A targeted approach to detect a specific mutation can be used for cases belonging to families with previous diagnosis. In index cases of either endemic and nonendemic regions that do not have a family history of disease, are difficult to confirm, and have atypical symptoms, *TTR* gene sequencing is required for the detection of both predicted and new amyloidogenic mutations \[[@R26],[@R27]\].

Postdiagnostic investigations
-----------------------------

Following diagnosis, the neuropathy stage and systemic extension of the disease should be determined in order to guide the next course of treatment (Table [4](#T4){ref-type="table"}) \[[@R3],[@R30],[@R31]\]. The three stages of TTR-FAP severity are graded according to a patient\'s walking disability and degree of assistance required \[[@R30]\]. Systemic assessment, especially of the heart, eyes, and kidney, is also essential to ensure all aspects of potential impact of the disease can be detected \[[@R10]\].

The goals of cardiac investigations are to detect serious conduction disorders with the risk of sudden death and infiltrative cardiomyopathy. Electrocardiograms (ECG), Holter-ECG, and intracardiac electrophysiology study are helpful to detect conduction disorders. Echocardiograms, cardiac magnetic resonance imaging, scintigraphy with bone tracers, and biomarkers (e.g., brain natriuretic peptide, troponin) can all help to diagnose infiltrative cardiomyopathy \[[@R10]\]. An early detection of cardiac abnormalities has obvious benefits to the patient, given that the prophylactic implantation of pacemakers was found to prevent 25% of major cardiac events in TTR-FAP patients followed up over an average of 4 years \[[@R32]^▪▪^\]. Assessment of cardiac denervation with 123-iodine meta-iodobenzylguanidine is a powerful prognostic marker in patients diagnosed with FAP \[[@R33]\].

### Eyes

Ophthalmological assessment is warranted to identify any ocular manifestations of TTR-FAP presenting as keratoconjunctivitis sicca, secondary glaucoma, vitreous opacities, or pupillary abnormalities \[[@R34]\].

### Kidney

It is also recommended that the monitoring of proteinuria and renal function form part of the TTR-FAP diagnostic approach. Microalbuminuria was detected in 75% of Portuguese patients with the Val30Met *TTR* mutation at different timepoints of the disease, with 21% eventually progressing to renal failure \[[@R35]\]. Following the onset of neuropathy, dialysis is generally required within 10 years \[[@R36]\].

Recommendations for the diagnosis of transthyretin familial amyloid polyneuropathy
----------------------------------------------------------------------------------

The current members of ATTReuNET acknowledge that the existing diagnostic approach taken for TTR-FAP is suboptimal. Questionnaire data show that most patients tend to see between three and four physicians before they receive an accurate diagnosis, and that a gap of 2--3 years between the emergence of first symptoms and an accurate diagnosis is not uncommon \[[@R11]\].

The group calls for a pooling of expertise across Europe, specifically in relation to diagnosis, by standardizing techniques and methods in pathological laboratories and facilitating access to *TTR* gene testing by providing referral channels to laboratories with the capacity to confirm diagnosis of amyloid disease. A gold standard process for TTR-FAP diagnosis requires clinical, pathological and genetic evidence in networks under the banner of NRCs. These are the first steps towards providing greater urgency to, and improving the quality of, TTR-FAP diagnosis.

Accurate diagnosis of sporadic cases of TTR-FAP presents a significant challenge, and special attention should be given to patients presenting with progressive, length-dependent axonal polyneuropathy predominantly affecting temperature and pain sensation (Table [2](#T2){ref-type="table"}). Particular attention should also be given to patients with autonomic dysfunction, involuntary major weight loss, carpal tunnel syndrome, and associated cardiac involvement \[[@R10],[@R26]\].

Disease management strategies for transthyretin familial amyloid polyneuropathy
-------------------------------------------------------------------------------

The management of TTR-FAP has expanded significantly in recent years; with the availability of pharmacotherapeutic alternatives, liver transplantation is no longer the only treatment option \[[@R26]\]. A comprehensive care package and a multidisciplinary approach are required to manage this multisystem disease. Targeted therapy is essential in the first instance to prevent further production of amyloid deposits. Thereafter, symptomatic therapy of sensorimotor and autonomic polyneuropathy and cardiac, renal, and ocular injury is required \[[@R6],[@R10]\]. Finally, genetic counselling to patients and relatives is recommended \[[@R37]\].

### Liver transplant

Prior to the pharmacotherapy era and as early as 1990, orthotopic liver transplant was the standard of care for patients with TTR-FAP \[[@R10],[@R26],[@R38]\]. A 20-year analysis of survival data from the Familial Amyloidotic Polyneuropathy World Transplant Registry of 2044 liver transplant patients reported a 20-year survival rate of 55.3% after treatment. Multivariate analysis revealed modified body mass index, onset of disease (\<50 years of age), disease duration before liver transplant, and *TTR* mutation type (Val30Met vs non-Val30Met) as independent and significant factors for better survival outcomes (i.e., patients with an early onset, Val30Met mutation and shorter duration of the disease have improved prognosis) \[[@R39]^▪▪^\]. In addition, a large cohort study of 215 consecutive patients who were followed up for 18 years at the French NRC identified five pejorative factors for survival after liver transplant: polyneuropathy disability score score not less than III, orthostatic hypotension, New York Heart Association (NYHA) functional class more than I, QRS complex duration at least 120 ms and thickened interventricular septum \[[@R40]\]. Risks can be computed using the online calculator by the French Referral Center for FAP and Other Rare Peripheral Neuropathies (NNERF) \[[@R41]\]. However, liver transplant is not readily accessible to many patients. ATTReuNET members reported an average wait of up to 1 year in France, Spain, Italy, and Sweden, increasing to 2--3 years for patients in Germany, the Netherlands, Portugal, and Cyprus (liver transplant not performed in Turkey).

Whereas liver transplant removes the main source of mutated *TTR*\[[@R42]--[@R44]\], it does not prevent progression of cardiac disease because the wild-type TTR may continue to further expand existing amyloid deposits in the heart \[[@R45]^▪▪^,[@R46]\]. Therefore, continued scrutiny of the cardiac system is warranted, as some patients will develop atrioventricular blocks or infiltrative cardiomyopathy several years or decades later; a combined heart and liver transplant may be recommended in selected patients with non-Val30Met mutations and cardiomyopathy \[[@R47],[@R48],[@R49]--[@R51]\]. However, ocular and central nervous system involvements often progress and/or appear after liver transplant due to the local synthesis of mutated TTR in retinal epithelium and coroid plexus \[[@R52]--[@R54]\].

### Tafamidis

Tafamidis is a first-in-class therapy that slows the progression of TTR amyloidogenesis by stabilizing the mutant TTR tetramer, thereby preventing its dissociation into monomers and amyloidogenic and toxic intermediates \[[@R55],[@R56]\]. Tafamidis is currently indicated in Europe for the treatment of TTR amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurological impairment \[[@R57]\].

In an 18-month, double-blind, placebo-controlled study of patients with early-onset Val30Met TTR-FAP, tafamidis was associated with a 52% lower reduction in neurological deterioration (*P* = 0.027), a preservation of nerve function, and TTR stabilization versus placebo \[[@R58]^▪▪^\]. However, only numerical differences were found for the coprimary endpoints of neuropathy impairment \[neuropathy impairment score in the lower limb (NIS-LL) responder rates of 45.3% tafamidis vs 29.5% placebo; *P* = 0.068\] and quality of life scores \[[@R58]^▪▪^\]. A 12-month, open-label extension study showed that the reduced rates of neurological deterioration associated with tafamidis were sustained over 30 months, with earlier initiation of tafamidis linking to better patient outcomes (*P* = 0.0435) \[[@R59]\]. The disease-slowing effects of tafamidis may be dependent on the early initiation of treatment. In an open-label study with Val30Met TTR-FAP patients with late-onset and advanced disease (NIS-LL score \>10, mean age 56.4 years), NIS-LL and disability scores showed disease progression despite 12 months of treatment with tafamidis, marked by a worsening of neuropathy stage in 20% and the onset of orthostatic hypotension in 22% of patients at follow-up \[[@R60]\].

Tafamidis is not only effective in patients exhibiting the Val30Met mutation; it also has proven efficacy, in terms of TTR stabilization, in non-Val30Met patients over 12 months \[[@R61]\]. Although tafamidis has demonstrated safe use in patients with TTR-FAP, care should be exercised when prescribing to those with existing digestive problems (e.g., diarrhoea, faecal incontinence) \[[@R60]\].

### Diflunisal

Diflunisal is a nonsteroidal anti-inflammatory drug (NSAID) that, similar to tafamidis, slows the rate of amyloidogenesis by preventing the dissociation, misfolding, and misassembly of the mutated TTR tetramer \[[@R62],[@R63]\]. Off-label use has been reported for patients with stage I and II disease, although diflunisal is not currently licensed for the treatment of TTR-FAP.

Evidence for the clinical effectiveness of diflunisal in TTR-FAP derives from a placebo-controlled, double-blind, 24-month study in 130 patients with clinically detectable peripheral or autonomic neuropathy \[[@R64]\]. The deterioration in NIS scores was significantly more pronounced in patients receiving placebo compared with those taking diflunisal (*P* = 0.001), and physical quality of life measures showed significant improvement among diflunisal-treated patients (*P* = 0.001). Notable during this study was the high rate of attrition in the placebo group, with 50% more placebo-treated patients dropping out of this 2-year study as a result of disease progression, advanced stage of the disease, and varied mutations.

One retrospective analysis of off-label use of diflunisal in patients with TTR-FAP reported treatment discontinuation in 57% of patients because of adverse events that were largely gastrointestinal \[[@R65]\]. Conclusions on the safety of diflunisal in TTR-FAP will depend on further investigations on the impact of known cardiovascular and renal side-effects associated with the NSAID drug class \[[@R66],[@R67]\].

### Symptomatic management

The management of symptoms associated with sensory-motor neuropathy and autonomic dysfunction should be initiated immediately following diagnosis and should be tailored to the individual patient \[[@R10]\]. Symptomatic treatment may include painkillers, antidiarrhoeal drugs, treatment of symptomatic orthostatic hypotension, diuretics for patients with cardiac failure, prophylactic pacemaker implantation for severe cardiac conduction disorders \[[@R32]^▪▪^\], or vitrectomy/trabeculectomy for the treatment for ocular amyloidosis or glaucoma, respectively \[[@R10]\].

### Emerging therapies

A number of new treatments for TTR-FAP are currently in phase II or III development. Posttranscriptional gene silencing is an approach that aims to inhibit the hepatic production of mutant and nonmutant TTR using small interfering RNAs \[[@R68]^▪▪^\] or antisense oligonucleotides \[[@R6]\]. Two phase III trials are ongoing, involving ALN-TTR02, an RNA interference (NCT01960348) \[[@R69]\], and ISIS 420915, an antisense oligonucleotide (NCT01737398) \[[@R70]\]. The removal of amyloid deposits has also been demonstrated in mouse models using a synergistic combination of doxycycline and tauroursodeoxycholic acid (TUDCA) \[[@R71]\], with ongoing clinical trials seeking to replicate these findings in patients (NCT01855360, NCT01171859) \[[@R72],[@R73]\]. Preliminary data from the latter, a small phase II study, are promising, showing stabilization of neuropathy scores over 12 months of treatment with no clinical progression of cardiac involvement \[[@R74]\]. Immunotherapy produces a regulated immune response against the specific amyloid protein by enhancing the clearance of these deposits with monoclonal antibodies. Currently, a number of antibodies \[e.g., monoclonal antibody NEOD001; the combination of a serum amyloid P (SAP) depleter (GSK2315698) and an anti-SAP antibody (GSK2398852)\] are undergoing testing in patients with various forms of amyloidosis (NCT01707264, NCT01777243) \[[@R75],[@R76]\].

A comprehensive care strategy
-----------------------------

ATTReuNETrecommends a multidisciplinary approach to the management of TTR-FAP including not only the diagnosing physician, but also a neurologist and a cardiologist, and possibly an ophthalmologist, in the initial assessment and subsequent reviews. Treatment strategies should also extend beyond antiamyloid therapy (surgical or pharmacotherapeutic) to include symptomatic treatment, the management of complications (e.g., cardiac failure, end-stage renal disease), and genetic counselling (to be detailed in the next part of this supplement \[[@R37]\]). Figure [1](#F1){ref-type="fig"} presents a comprehensive treatment algorithm for TTR-FAP, developed by the group. Physicians should note that existing treatments are most effective in patients with stage I TTR-FAP, with limited data available on the efficacy in more advanced stages, different genotypes, and late-onset variants.

![Strategy for specific therapy in TTR-FAP. CI, contraindications; LT, liver transplantation; TTR-FAP, transthyretin familial amyloid polyneuropathy. ^a^CI for LT include: active and uncontrolled cancer; aged \> 50 years for males and \> 70 years for females \[[@R39]^▪▪^,[@R77]\], except for Italy (aged \>65 years); modified body mass index below 800 kg/m^2^·g/L; some non-Val30Met *TTR* mutations; cardiac insufficiency. ^b^Stage I: walking unaided outside. ^c^Stage II: walking with aid. ^d^Protocol clinical trial for antisense oligonucleotides, small interfering RNA, combination doxycycline--tauroursodeoxycholic acid; or diflunisal off-label. Adapted from \[[@R1]\].](coneu-29-s14-g002){#F1}

Ongoing monitoring is crucial and permits systematic tracking of TTR-FAP disease progression. Figure [2](#F2){ref-type="fig"} describes an algorithm for patient follow-up during active treatment. Clinical and biochemical assessment should take place no later than 3 months from treatment initiation, with a full, multidisciplinary consultation at 6 and 12 months. Patients should be assessed biannually or as required at their TTR-FAP clinic, with monitoring maintained throughout their lives. Ideally, the review should involve a neurologist, a cardiologist, and an internal medicine specialist (depending on local practice) at each visit. Regular follow-up with the multidisciplinary team can help to diminish a patient\'s anxiety and aid the acceptance of the diagnosis, as well as enable the detection of new manifestations of amyloid deposits and other disease symptoms. Patients with more advanced disease (stage II or III) should be seen on a quarterly basis, whereas those who respond well to treatment can be followed up less regularly.

![Algorithm for patient follow-up during treatment for TTR-FAP (compiled from clinical experience of ATTReuNET in March 2014). AE, adverse event; ECG, electrocardiogram; mBMI, modified body mass index; NIS, Neurological Impairment Scale; OH, orthostatic hypotension; PND, modified polyneuropathy disability score; TTR-FAP, transthyretin familial amyloid polyneuropathy; UTI, urinary tract infection. ^a^Quarterly basis for those with more advanced (stage II, III) disease unless responding well to treatment.](coneu-29-s14-g003){#F2}

CONCLUSION
==========

TTR-FAP is a rare but life-threatening disease. Given the limited window for treatment effectiveness, an early and accurate diagnosis followed by appropriate therapeutic intervention is critical. The establishment of direct referral systems through NRCs across Europe allows the pooling of clinical resources and expertise to help reduce misdiagnosis and delay to treatment. Increased awareness of existing nonclassical TTR-FAP patient groups (e.g., sporadic cases) will help to direct and streamline the diagnostic process, enabling early implementation of specific strategies and better patient outcomes. The recent emergence of alternatives to liver transplantation has greatly enhanced the treatment options available to patients with TTR-FAP.
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###### Supplemental Digital Content

###### 

Summary of diagnostic methods and respective aims for TTR amyloidosis^a^

  Investigation                                    Sensitivity                Specificity    Aim                                                 References
  ------------------------------------------------ -------------------------- -------------- --------------------------------------------------- --------------------
  Biopsy sites                                                                                                                                   
   Sural nerve biopsy                              79--80% TTR                High           Detecting amyloid deposits                          \[12,13^▀^,15^▀^\]
   Labial salivary gland biopsy                    91% Val30Met early onset   High           Detecting amyloid deposits                          \[[@R8]\]
   Abdominal fat pad biopsy                        14--83%                    High           Detecting amyloid deposits                          [@R16]
  Pathology test methods                           \[[@R10]\]                                                                                    
   Congo red staining                              Medium--high               High           Detecting amyloid deposits                          
   Polarized microscopy examination                High                       High           Green birefringence                                 
   Immunohistochemistry with anti-TTR antibodies   High                       Medium--high   Detecting TTR deposits                              
  Genetic tests                                    \[[@R10]\]                                                                                    
   PCR-RFLP                                        High                       High           Detecting predicted mutations in the *TTR* gene     
   Real-time PCR (melting curve analysis)          High                       High           Detecting predicted mutations in the *TTR* gene     
   Sequencing[^b^](#TF1-2){ref-type="table-fn"}    High                       High           Screening for unknown mutations in the *TTR* gene   
   PCR-SSCP                                        Medium                     Medium         Detecting predicted mutations in the *TTR* gene     
  Mass spectrometry tests                          [@R17]                                                                                        
   LMD/MS                                          Approx. 100%               High           Determining specific type of amyloid deposits       

LMD/MS, laser microdissection mass spectrometric-based proteomic analysis; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSCP, single-strand conformation polymorphism; TTR, transthyretin.

^a^Adapted from [@R1] and \[[@R10]\].

^b^Sequencing is essential for diagnosis of TTR amyloidosis (sporadic cases).

###### 

ATTReuNET-recommended diagnosis of nonendemic (usually late-onset) TTR-FAP: Key points of note

  Typical clinical features of later disease (average 4 years post onset; the usual delay for diagnosis)
  --------------------------------------------------------------------------------------------------------
  Progressive idiopathic polyneuropathy
  Early walking difficulties, using aid support
  Initial complaint: \[[@R20]\]
   Sensory-motor neuropathic symptoms (80%)
   Autonomic symptoms (10%)
  Examination: All modality sensory deficit
  Presence of family history (less than 50%)
  Autonomic neuropathy without diabetes (uncommon at the onset)
   Neurogenic orthostatic hypotension
   Digestive symptoms (e.g., diarrhoea, constipation)
   Urogenital symptoms (e.g., erectile dysfunction)
  Unintentional major weight loss
  Associated cardiac symptomatology (syncope, dyspnoea)

  Diagnosis
  ----------------------------------------------------------------------
  DNA testing for *TTR* mutation (sequencing) first line in the future
  Tissue biopsy confirms amyloid deposition

ATTReuNET, European Network for TTR-FAP; TTR, transthyretin; TTR-FAP, transthyretin familial amyloid polyneuropathy.

###### 

ATTReuNET-compiled type and frequency of TTR-FAP biopsies performed across Europe

                                                                                 Country                                                                                              
  ------------------------------------------------------------------------------ --------- ----- ------------------------------------------ ---- -------- ----- -------- ------ ----- -----
  Estimated number of TTR-FAP cases declared, *n*                                2000      50    250                                        87   120      80    20--30   500    500   200
  Site of biopsy, % performed in each centre[^a^](#TF3-1){ref-type="table-fn"}                                                                                                        
   Abdominal fat aspiration                                                      3         --    100                                        --   40--60   100   10--15   --     50    85
   Sural nerve                                                                   2         --    --                                         --   15--20   --    75       40     15    --
   Rectal                                                                        --        100   --                                         80   25--40   25    --       --     30    --
   Labial salivary gland                                                         95        --    --                                         6    --       --    10--15   100    5     5
   Gastric                                                                       --        --    20--80[^b^](#TF3-2){ref-type="table-fn"}   --   --       --    --       5      --    --
   Heart                                                                         --        --    5                                          2    --       10    --       \< 5   --    10
   Others                                                                        --        --    0--5[^c^](#TF3-3){ref-type="table-fn"}     12   --       --    --       --     --    --
  Types of biopsies performed, *n*                                               3         1     3                                          5    3        3     3        4      4     3

ATTReuNET, European Network for TTR-FAP; TTR-FAP, transthyretin familial amyloid polyneuropathy.

^a^Where total numbers exceed 100%, more than one biopsy was performed.

^b^As part of routine evaluation of gastric function.

^c^Skin, *n* = 6; renal, *n* = 6.

###### 

TTR-FAP stages of disease according to symptom severity

  Stage of disease                                                                                                                                                                                                         Symptoms                                                                          PND                                                                     Treatment suggestions                                                                Comments
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------
  Stage 0                                                                                                                                                                                                                  Asymptomatic                                                                                                                                              Follow-up according to patient\'s age and mutation type                              
  Stage I                                                                                                                                                                                                                  Mild, ambulatory, symptoms at lower limbs limited                                 I. Sensory disturbances in extremities but preserved walking capacity   Confirm diagnosis                                                                    Best candidates for liver transplant are early onset Met30 (young with mild symptoms)
                                                                                                                                                                                                                                                                                                             II\. Difficulties in walking but without the need for a walking stick   First-line pharmacotherapy: tafamidis (EU approved) or diflunisal if not available   
                                                                                                                                                                                                                                                                                                                                                                                     Liver transplant                                                                     
                                                                                                                                                                                                                                                                                                                                                                                     Follow up every 6 months for disease progression, especially cardiac                 
  Stage II                                                                                                                                                                                                                 Moderate, further neuropathic deterioration, ambulatory but requires assistance   IIIa. One stick or one crutch required for walking                      Diflunisal may slow progression of the disease                                       
                                                                                                                                                                                                                                                                                                             IIIb. Two sticks or two crutches required for walking                                                                                                        
  Stage III                                                                                                                                                                                                                Severe, bedridden/wheelchair-bound with generalized weakness                      IV\. Patient confined to a wheelchair or bed                            No evidence for pharmacotherapy                                                      
                                                                                                                                                                                                                                                                                                                                                                                     Treatment through clinical trial                                                     
  **Recommended assessments**                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Neuropathic: Modified Norris score, modified polyneuropathy disability (PND) score, neuropathy impairment score-weakness score (onset of orthostatic hypotension ++), scintigraphy with metaiodobenzylguanidine (mIBG)                                                                                                                                                                                                                                                  
  Electrophysiological: Quantitative sensation tests, quantitative autonomic tests, electromyographic test, sympathetic skin response                                                                                                                                                                                                                                                                                                                                     
  Cardiac: ECG, Holter ECG, BNP/NT-proBNP, troponin, and echocardiography. When necessary: MRI, 'bone' DPD scintigraphy, intracardiac electrophysiological study                                                                                                                                                                                                                                                                                                          
  Renal: Urinalysis                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  General: Physical and clinical examination include weight (body mass index), blood test including s-albumin, quality of life                                                                                                                                                                                                                                                                                                                                            

BNP, brain natriuretic peptide; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; ECG, electrocardiography; NT-proBNP, N-terminal of the prohormone BNP; TTR-FAP, transthyretin familial amyloid polyneuropathy. Adapted from \[3,30,31\].
